- Home
- PPCB vs CMND Comparison
PPCB vs CMND Comparison
Compare PPCB & CMND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PPCB | CMND |
|---|---|---|
| Founded | 2007 | 2017 |
| Country | Australia | Canada |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6M | 2.6M |
| IPO Year | 2011 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PPCB | CMND |
|---|---|---|
| Price | $0.53 | $0.79 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 238.1K | ★ 381.4K |
| Earning Date | 05-16-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.06 | $0.07 |
| 52 Week High | $6.79 | $4.66 |
Technical Indicators
Market Signals| Indicator | PPCB | CMND |
|---|---|---|
| Relative Strength Index (RSI) | 34.21 | 27.87 |
| Support Level | $0.12 | $0.77 |
| Resistance Level | $1.29 | $1.27 |
| Average True Range (ATR) | 0.08 | 0.08 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 1.54 | 6.47 |
Price Performance
Historical ComparisonAbout PPCB Propanc Biopharma Inc.
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.
About CMND Clearmind Medicine Inc.
Clearmind Medicine Inc is a clinical-stage pharmaceutical company engaged in Phase I/IIa clinical trials of novel psychedelic medicines. The Company focuses on developing treatments for mental health disorders, including alcohol use disorder (AUD), binge drinking, and eating disorders. Its activities are centered on the research and development of 5-methoxy-2-aminoindane (MEAI). It operates through a single research and development segment, which is conducted in Israel.